Claims in this piece are observable and methodological — no client or benchmark data used.
By the time an overseas buyer sends your company an enquiry, they have usually already decided you are worth a conversation. Anyone who has worked in pharmaceutical business development has heard the sentence that gives it away — “we’d been evaluating your company for months before we got in touch.” The harder question is what happened in those months, during the research stage, when the buyer was quietly narrowing a wide field to a short one — and when your company was either included or passed over without anyone telling you.
Increasingly, part of that narrowing happens in a conversation with an AI assistant. A procurement lead, a technical evaluator, or a business development manager at an overseas pharmaceutical company types a plain-language question into ChatGPT, Gemini, or Perplexity and reads what comes back — before opening a single company website. As the parent article on how buyers now discover CDMOs argues, an AI can only work with what your public presence makes clear. The Discoverability Principle holds: AI systems cannot recommend what they cannot clearly understand.
And here is the part worth sitting with: the buyer is not asking the AI who is best, or who is cheapest. They are asking who is relevant enough to investigate further. That is a lower bar, and a more dangerous one to miss — because failing it means you are never even considered. So the most practical way to see your company as an AI presents it is to look at the questions buyers actually ask, and what each one is really testing beneath the surface.
The five questions — and what each one tests
1. “Which contract manufacturers in India have EU GMP-approved facilities for sterile injectables?”
Beneath the wording, the buyer is asking: can this company even make what I need? It is a capability-and-compliance test, and it turns on whether your core manufacturing capability and regulatory status are stated specifically enough to be matched to a precise requirement. Companies that describe themselves as offering “a broad range of dosage forms” and “world-class quality” struggle here, because vague language cannot be mapped to a specific need.
2. “Which Indian CDMOs have experience with oncology or high-potency (HPAPI) products?”
The real question is: do they resemble my particular challenge? This is a specialised-capability test, and it rewards depth over breadth. General-purpose positioning loses to demonstrated specialisation. If your HPAPI containment capability or oncology handling experience exists but is not visible and specific in your public presence, it does not help you at this stage.
3. “Which manufacturers have a strong regulatory track record with the US FDA or under EU GMP?”
Underneath: can I trust them with a regulated product? A trust-and-evidence test. It turns on whether your regulatory standing is legible to an outsider — inspection history, approvals, and the certifications a buyer cares about, discoverable and unambiguous rather than implied, buried, or absent.
4. “Who can support technology transfer for a complex formulation?”
The buyer is really asking: are they mature enough for the hard part? A capability-maturity test. It rewards companies that signal the harder, higher-value competencies rather than only baseline manufacturing. These are exactly the capabilities that win premium work — and exactly the ones manufacturers most often under-describe.
5. “Which CDMOs are considered reliable and quality-focused for regulated markets?”
The question beneath is simple: is this company worth contacting first? A reputation-and-coherence test. It turns on whether the sense of your company that emerges across its public footprint is consistent and credible enough to be mentioned with confidence.
Read together, these five questions test five things:
Clarity of capability · Depth of specialisation · Evidence of regulatory standing · Maturity of capability · Coherence of reputation.
That is, in effect, the standard against which an AI assembles a shortlist — and none of it depends on the AI having private knowledge of your company. It works only from what you have made public.
Why a strong company can still fail these questions
The uncomfortable insight is that a company can be genuinely excellent at all five things and still be passed over — because being excellent and being legible are different. A manufacturer with an outstanding sterile fill-finish operation and a clean FDA history can still be absent from the answer if that operation is described in generic language, the regulatory record is hard to find, and the public picture of the company is thin or inconsistent.
Experienced buyers know this instinctively, which is why many of them have learned to distrust the website that says everything — “world-class,” “end-to-end,” “innovative,” “global solutions.” Those phrases sound impressive and communicate almost nothing. Specificity builds confidence; generalisation creates uncertainty. An AI assistant, working from the same public text, reaches the same difficulty for the same reason.
This is not a marketing problem in the ordinary sense. It is a discoverability problem — the gap between what your company genuinely is and what an AI can confidently determine it to be from the outside. That gap is where lost enquiries live, and it rarely announces itself. No one writes to say you weren’t legible enough to include.
See your own answers
You do not have to take any of this on trust, and checking it costs nothing. Open ChatGPT, Gemini, and Perplexity, and ask each of the five questions above that fit your business — as literally as a buyer would phrase them. Then read the answers with one thing in mind: not whether the AI is right about your company, but whether it can say anything specific about you at all. Compare the platforms. Notice where you appear, where you don’t, and what each seems confident about versus vague on.
That exercise is the first honest diagnostic of your AI Visibility. It will not tell you how to fix what you find — but it will show you, concretely, whether the buyers asking these questions are being pointed toward your company or past it.
If an overseas procurement team began researching suppliers today using AI-assisted search, would your company be understood with the same clarity it would have after a two-hour capability presentation? If the honest answer is “probably not,” the gap is not in your capability — it is in how that capability is communicated before the first conversation ever takes place.
Emerivo helps pharmaceutical manufacturers and research organisations — TPMs, CMOs, CDMOs, and CROs — make genuine expertise legible to buyers and AI assistants alike. The AI Discovery Audit™ examines exactly the questions above against your own public presence — to identify opportunities for improvement, not to promise rankings or recommendations. For the wider shift behind this, read the parent article: Why Overseas Pharma Buyers Are Changing How They Discover CDMOs.
Frequently asked questions
Not instead — before. Formal qualification, audits, and commercial discussion still happen directly with you. What has moved is the earlier research stage, where the shortlist is narrowed. You can reproduce the behaviour yourself by running the questions above.
No. No credible organisation can guarantee how an AI assistant will respond, and answers vary across platforms and change over time. Clarity improves the odds of being understood; it does not purchase a recommendation.
Answering real buyer questions clearly is sound. But the deeper point is not to game five prompts — it is to make your genuine capability, specialisation, and regulatory standing legible everywhere, so any reasonable version of these questions finds a clear answer.